Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Shares in Novo Nordisk, one of Europe’s most valuable companies, jumped 8 per cent on Friday after the pharmaceutical group announced positive results from the latest trial of weight-loss treatments.
The early stage trial found that people treated with amycretin lost up to 22 per cent of their body weight after using the drug for 36 weeks.
Martin Lange, executive vice-president for development at Novo Nordisk, said the group was “very encouraged” by the results of the amycretin trial for people who are overweight or obese.
The company is now planning further development of the treatment.
The shares, which had fallen sharply since reaching a peak of DKr1028 last summer, rose 8 per cent to DKr627 on Friday.
This is a developing story
Read the full article here
